Strides Pharma Science Limited

Authum Investment & Infrastructure reduced its stake in Strides Pharma Science Limited from 1.30% to 1.28%, selling 19,504 shares for ₹2.10 crore at ₹1074.90 apiece.

A pharmaceutical manufacturer engaged in developing and producing a diverse range of drug formulations for global distribution. The company operates across multiple therapy segments and maintains manufacturing facilities serving customers in over 100 countries. Strides Pharma has pursued strategic acquisitions and inorganic expansion to strengthen its market presence, diversify business segments, enhance therapy offerings, and build robust production infrastructure.

BSE-listed NBFC (market cap ~Rs 38,000 cr) controlled by Sanjay and Alpana Dangi, with around Rs 15,300 cr deployed across listed and unlisted Indian equities and credit. One of India's most aggressive listed proprietary investment vehicles, with concentrated multi-bagger positions and disclosed stakes in 10+ listed companies.